Download PDF
Semin Reprod Med 2017; 35(06): 510-522
DOI: 10.1055/s-0037-1606302
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Current and Emerging Medical Treatments for Uterine Fibroids

Kristof Chwalisz
1   Research and Development, General Medicine, AbbVie Inc., North Chicago, Illinois
,
Hugh Taylor
2   Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
› Author Affiliations
Further Information

Publication History

Publication Date:
03 November 2017 (online)

    Permissions and Reprints

Abstract

Uterine fibroids (leiomyomata) are common uterine neoplasms that are often associated with detrimental symptoms, such as heavy menstrual bleeding, dysmenorrhea, and pressure-related symptoms, which often lead to surgical intervention, including hysterectomy. Although our understanding of the pathophysiology of uterine fibroids, particularly their dependency on progesterone and the role of growth factors, has increased during the past two decades, the medical options currently approved by the United States Food and Drug Administration are limited and are only used for short-term symptom management. A long-term, safe, and effective treatment is not yet available in the United States. However, emerging medical treatments that are currently under clinical development, including progesterone receptor modulators and oral gonadotropin-releasing hormone antagonists, offer hope of new long-term medical therapies for symptomatic uterine fibroids as an alternative to surgery. Herein, we discuss the current and emerging medical therapies for fibroids based on evidence from randomized clinical trials.

Keywords

uterine fibroids - progesterone receptor modulators - oral GnRH antagonists
 

  • References

  • 1 Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188 (01) 100-107
    CrossrefPubMedGoogle Scholar
  • 2 Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010; 28 (03) 204-217
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Huyck KL, Panhuysen CI, Cuenco KT. , et al. The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol 2008; 198 (02) 168.e1-168.e9
    CrossrefPubMedGoogle Scholar
  • 4 Jacoby VL, Fujimoto VY, Giudice LC, Kuppermann M, Washington AE. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol 2010; 202 (06) 514-521
    CrossrefPubMedGoogle Scholar
  • 5 Peddada SD, Laughlin SK, Miner K. , et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci U S A 2008; 105 (50) 19887-19892
    CrossrefPubMedGoogle Scholar
  • 6 Carlson KJ, Nichols DH, Schiff I. Indications for hysterectomy. N Engl J Med 1993; 328 (12) 856-860
    CrossrefPubMedGoogle Scholar
  • 7 Wright JD, Herzog TJ, Tsui J. , et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 2013; 122 (2, Pt 1): 233-241
    CrossrefPubMedGoogle Scholar
  • 8 Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012; 206 (03) 211.e1-211.e9
    CrossrefPubMedGoogle Scholar
  • 9 Carls GS, Lee DW, Ozminkowski RJ, Wang S, Gibson TB, Stewart E. What are the total costs of surgical treatment for uterine fibroids?. J Womens Health (Larchmt) 2008; 17 (07) 1119-1132
    CrossrefPubMedGoogle Scholar
  • 10 Borah BJ, Nicholson WK, Bradley L, Stewart EA. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol 2013; 209 (04) 319.e1-319.e20
    CrossrefPubMedGoogle Scholar
  • 11 Buttram Jr VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36 (04) 433-445
    CrossrefPubMedGoogle Scholar
  • 12 Stovall DW. Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol 2001; 44 (02) 364-371
    CrossrefPubMedGoogle Scholar
  • 13 Stewart EA. Uterine fibroids. Lancet 2001; 357 (9252): 293-298
    CrossrefPubMedGoogle Scholar
  • 14 Peric H, Fraser IS. The symptomatology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20 (04) 547-555
    CrossrefPubMedGoogle Scholar
  • 15 Olive DL, Pritts EA. Fibroids and reproduction. Semin Reprod Med 2010; 28 (03) 218-227
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Guo XC, Segars JH. The impact and management of fibroids for fertility: an evidence-based approach. Obstet Gynecol Clin North Am 2012; 39 (04) 521-533
    CrossrefPubMedGoogle Scholar
  • 17 Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009; 91 (04) 1215-1223
    CrossrefPubMedGoogle Scholar
  • 18 Somigliana E, Vercellini P, Daguati R, Pasin R, De Giorgi O, Crosignani PG. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update 2007; 13 (05) 465-476
    CrossrefPubMedGoogle Scholar
  • 19 Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 2011; 29 (05) 383-390
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Fraser IS, Critchley HO, Munro MG. Abnormal uterine bleeding: getting our terminology straight. Curr Opin Obstet Gynecol 2007; 19 (06) 591-595
    CrossrefPubMedGoogle Scholar
  • 21 Fraser IS, Critchley HO, Munro MG. An international perspective on abnormal uterine bleeding. Semin Reprod Med 2011; 29 (05) 375-376
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Fraser IS, Critchley HO, Munro MG, Broder M. ; Writing Group for this Menstrual Agreement Process. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007; 87 (03) 466-476
    CrossrefPubMedGoogle Scholar
  • 23 Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding?. Hum Reprod 2007; 22 (03) 635-643
    CrossrefPubMedGoogle Scholar
  • 24 Munro MG, Critchley HO, Fraser IS. ; FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011; 95 (07) 2204-2208 , 2208.e1–2208.e3
    CrossrefPubMedGoogle Scholar
  • 25 Rybo G. Menstrual blood loss in relation to parity and menstrual pattern. Acta Obstet Gynecol Scand 1966; 45 (Suppl. 07) 25-45
    PubMedGoogle Scholar
  • 26 Higham JM, O'Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97 (08) 734-739
    CrossrefPubMedGoogle Scholar
  • 27 Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85 (06) 977-982
    CrossrefPubMedGoogle Scholar
  • 28 Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM. Determination of total menstrual blood loss. Fertil Steril 2001; 76 (01) 125-131
    CrossrefPubMedGoogle Scholar
  • 29 Larsen L, Coyne K, Chwalisz K. Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reprod Sci 2013; 20 (06) 680-687
    CrossrefPubMedGoogle Scholar
  • 30 Eder S, Baker J, Gersten J, Mabey RG, Adomako TL. Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids. Womens Health (Lond) 2013; 9 (04) 397-403
    PubMedGoogle Scholar
  • 31 Clevenger-Hoeft M, Syrop CH, Stovall DW, Van Voorhis BJ. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol 1999; 94 (04) 516-520
    PubMedGoogle Scholar
  • 32 Novak ER, Woodruff JD. Myomas and other benign tumors of the uterus. In: Novak's Gynecologic and Obstetric Pathology. Philadelphia, PA: WB Saunders; 1979: 260-279
    Google Scholar
  • 33 Lumsden MA. Fibroids and menorrhagia. In: Shaw RW. , ed. Uterine Fibroids: Time for Review. Lancaster: Parthenon Publishing; 1992: 57-68
    Google Scholar
  • 34 Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996; 2 (04) 295-306
    CrossrefPubMedGoogle Scholar
  • 35 Ciarmela P, Islam MS, Reis FM. , et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update 2011; 17 (06) 772-790
    CrossrefPubMedGoogle Scholar
  • 36 Rackow BW, Taylor HS. Submucosal uterine leiomyomas have a global effect on molecular determinants of endometrial receptivity. Fertil Steril 2010; 93 (06) 2027-2034
    CrossrefPubMedGoogle Scholar
  • 37 Sinclair DC, Mastroyannis A, Taylor HS. Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3. J Clin Endocrinol Metab 2011; 96 (02) 412-421
    CrossrefPubMedGoogle Scholar
  • 38 Doherty LF, Taylor HS. Leiomyoma-derived transforming growth factor-β impairs bone morphogenetic protein-2-mediated endometrial receptivity. Fertil Steril 2015; 103 (03) 845-852
    CrossrefPubMedGoogle Scholar
  • 39 Lee KY, Jeong JW, Wang J. , et al. Bmp2 is critical for the murine uterine decidual response. Mol Cell Biol 2007; 27 (15) 5468-5478
    CrossrefPubMedGoogle Scholar
  • 40 Jabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. Endocr Rev 2006; 27 (01) 17-46
    CrossrefPubMedGoogle Scholar
  • 41 Casslén B, Gustavsson B. Expression of cell membrane receptors for urokinase plasminogen activator (u-PA) in the human endometrium increases during the ovarian cycle. Fibrinolysis 1991; 5: 243-248
    PubMedGoogle Scholar
  • 42 Casslén B, Astedt B. Fibrinolytic activity of human uterine fluid. Acta Obstet Gynecol Scand 1981; 60 (01) 55-58
    CrossrefPubMedGoogle Scholar
  • 43 Casslén B, Nordengren J, Gustavsson B, Nilbert M, Lund LR. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor. J Clin Endocrinol Metab 1995; 80 (09) 2776-2784
    PubMedGoogle Scholar
  • 44 Schatz F, Lockwood CJ. Progestin regulation of plasminogen activator inhibitor type 1 in primary cultures of endometrial stromal and decidual cells. J Clin Endocrinol Metab 1993; 77 (03) 621-625
    PubMedGoogle Scholar
  • 45 Gleeson NC. Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia. Am J Obstet Gynecol 1994; 171 (01) 178-183
    CrossrefPubMedGoogle Scholar
  • 46 Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90 (01) 204-208
    PubMedGoogle Scholar
  • 47 Horne AW, Critchley HO. The effect of uterine fibroids on embryo implantation. Semin Reprod Med 2007; 25 (06) 483-489
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Barbarisi A, Petillo O, Di Lieto A. , et al. 17-beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol 2001; 186 (03) 414-424
    CrossrefPubMedGoogle Scholar
  • 49 Doherty L, Mutlu L, Sinclair D, Taylor H. Uterine fibroids: clinical manifestations and contemporary management. Reprod Sci 2014; 21 (09) 1067-1092
    CrossrefPubMedGoogle Scholar
  • 50 Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995; 172 (1, Pt 1): 14-18
    CrossrefPubMedGoogle Scholar
  • 51 Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005; 26 (03) 423-438
    CrossrefPubMedGoogle Scholar
  • 52 Bulun SE. Uterine fibroids. N Engl J Med 2013; 369 (14) 1344-1355
    CrossrefPubMedGoogle Scholar
  • 53 Englund K, Blanck A, Gustavsson I. , et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 1998; 83 (11) 4092-4096
    PubMedGoogle Scholar
  • 54 Brandon DD, Bethea CL, Strawn EY. , et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993; 169 (01) 78-85
    CrossrefPubMedGoogle Scholar
  • 55 Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999; 14 (11) 2844-2850
    CrossrefPubMedGoogle Scholar
  • 56 Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989; 160 (03) 637-641
    CrossrefPubMedGoogle Scholar
  • 57 Harrison-Woolrych ML, Charnock-Jones DS, Smith SK. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 1994; 78 (05) 1179-1184
    PubMedGoogle Scholar
  • 58 Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 2010; 151 (06) 2433-2442
    CrossrefPubMedGoogle Scholar
  • 59 A randomized placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of ulipristal acetate for the intermittent treatment of abnormal uterine bleeding associated with leiomyomas. Available at: https://clinicaltrials.gov/ct2/show/NCT02147158?term=ulipristal+acetate+and+uterine+fibroids &rank = 9 . Accessed June 13, 2017
    PubMedGoogle Scholar
  • 60 Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006; (02) CD003855
    PubMedGoogle Scholar
  • 61 Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011; 117 (04) 777-787
    CrossrefPubMedGoogle Scholar
  • 62 Fraser IS, Römer T, Parke S. , et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod 2011; 26 (10) 2698-2708
    CrossrefPubMedGoogle Scholar
  • 63 Stovall TG, Muneyyirci-Delale O, Summitt Jr RL, Scialli AR. ; Leuprolide Acetate Study Group. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Obstet Gynecol 1995; 86 (01) 65-71
    CrossrefPubMedGoogle Scholar
  • 64 Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001; 2 (02) CD000547
    PubMedGoogle Scholar
  • 65 Lukes AS, Moore KA, Muse KN. , et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116 (04) 865-875
    CrossrefPubMedGoogle Scholar
  • 66 Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BW. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database Syst Rev 2013; (02) CD008994
    PubMedGoogle Scholar
  • 67 Donnez J, Tatarchuk TF, Bouchard P. , et al; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366 (05) 409-420
    CrossrefPubMedGoogle Scholar
  • 68 Donnez J, Tomaszewski J, Vázquez F. , et al; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366 (05) 421-432
    CrossrefPubMedGoogle Scholar
  • 69 Smith OP, Jabbour HN, Critchley HO. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod 2007; 22 (05) 1450-1456
    CrossrefPubMedGoogle Scholar
  • 70 Cameron IT, Haining R, Lumsden MA, Thomas VR, Smith SK. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol 1990; 76 (01) 85-88
    PubMedGoogle Scholar
  • 71 Gleeson N, Devitt M, Sheppard BL, Bonnar J. Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding. Br J Obstet Gynaecol 1993; 100 (08) 768-771
    CrossrefPubMedGoogle Scholar
  • 72 Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; (04) CD000249
    PubMedGoogle Scholar
  • 73 Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994; 73 (03) 274-277
    CrossrefPubMedGoogle Scholar
  • 74 Lysteda (Tranexamic Acid). Prescribing information. Ferring Pharmaceuticals, Parsippany, NJ. Available at: http://www.ferringusa.com/wp-content/uploads/2016/07/LystedaPI_3.2016.pdf . Accessed October 10, 2017
    PubMedGoogle Scholar
  • 75 Qin J, Yang T, Kong F, Zhou Q. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies. Arch Gynecol Obstet 2013; 288 (01) 139-148
    CrossrefPubMedGoogle Scholar
  • 76 Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet 2011; 112 (02) 126-130
    CrossrefPubMedGoogle Scholar
  • 77 Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2011; 16 (04) 258-269
    CrossrefPubMedGoogle Scholar
  • 78 Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49 (01) 56-72
    CrossrefPubMedGoogle Scholar
  • 79 Mirena (Levonorgestrel-Releasing Intrauterine System). Prescribing information. Bayer HealthCare Pharmaceuticals, Whippany, NJ. Available at: https://labeling.bayerhealthcare.com/html/products/pi/mirena_PI.pdf . Accessed October 10, 2017
    PubMedGoogle Scholar
  • 80 Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2015; (04) CD002126
    PubMedGoogle Scholar
  • 81 Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010; 82 (01) 41-55
    CrossrefPubMedGoogle Scholar
  • 82 National Institute for Health and Care Excellence. Heavy Menstrual Bleeding. 2007: 1-164
    PubMedGoogle Scholar
  • 83 Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105 (06) 592-598
    CrossrefPubMedGoogle Scholar
  • 84 Carr BR, Marshburn PB, Weatherall PT. , et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993; 76 (05) 1217-1223
    PubMedGoogle Scholar
  • 85 Rogers PA, Martinez F, Girling JE. , et al. Influence of different hormonal regimens on endometrial microvascular density and VEGF expression in women suffering from breakthrough bleeding. Hum Reprod 2005; 20 (12) 3341-3347
    CrossrefPubMedGoogle Scholar
  • 86 Knobil E. On the control of gonadotropin secretion in the rhesus monkey. Recent Prog Horm Res 1974; 30 (0): 1-46
    PubMedGoogle Scholar
  • 87 Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol 2013; 9 (08) 451-466
    CrossrefPubMedGoogle Scholar
  • 88 Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. ; The Leuprolide Study Group. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 1991; 77 (05) 720-725
    PubMedGoogle Scholar
  • 89 Chwalisz K, Surrey E, Stanczyk FZ. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod Sci 2012; 19 (06) 563-571
    CrossrefPubMedGoogle Scholar
  • 90 Moroni RM, Martins WP, Ferriani RA. , et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev 2015; (03) CD010854
    PubMedGoogle Scholar
  • 91 Morris EP, Rymer J, Robinson J, Fogelman I. Efficacy of tibolone as “add-back therapy” in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril 2008; 89 (02) 421-428
    CrossrefPubMedGoogle Scholar
  • 92 Spitz IM. Progesterone receptor antagonists and selective progesterone receptor modulators (SPRMs). Semin Reprod Med 2005; 23 (01) 3-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 93 Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005; 11 (03) 293-307
    CrossrefPubMedGoogle Scholar
  • 94 Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004; 25 (01) 45-71
    CrossrefPubMedGoogle Scholar
  • 95 Wagenfeld A, Bone W, Schwede W, Fritsch M, Fischer OM, Moeller C. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod 2013; 28 (08) 2253-2264
    CrossrefPubMedGoogle Scholar
  • 96 Philibert D. RU38486: an original multifaceted antihormone in vivo. In: Agarwal MK. , ed. Adrenal Steroid Antagonism. New York, NY: Walter de Gruyter and Co.; 1984: 77-101
    Google Scholar
  • 97 Elger W, Fähnrich M, Beier S, Qing SS, Chwalisz K. Endometrial and myometrial effects of progesterone antagonists in pregnant guinea pigs. Am J Obstet Gynecol 1987; 157 (4, Pt 2): 1065-1074
    CrossrefPubMedGoogle Scholar
  • 98 Elger W, Beier S, Chwalisz K. , et al. Studies on the mechanisms of action of progesterone antagonists. J Steroid Biochem 1986; 25 (5B): 835-845
    CrossrefPubMedGoogle Scholar
  • 99 DeManno D, Elger W, Garg R. , et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003; 68 (10-13): 1019-1032
    CrossrefPubMedGoogle Scholar
  • 100 Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003; 101 (02) 243-250
    PubMedGoogle Scholar
  • 101 Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007; 87 (06) 1399-1412
    CrossrefPubMedGoogle Scholar
  • 102 Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994; 9 (Suppl. 01) 116-120
    CrossrefPubMedGoogle Scholar
  • 103 Esmya (ulipristal). 2012 ; Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines /002041/huma n med 001542.jsp&mid = WC0b01ac058001d124 . Accessed October 10, 2017
    PubMed
  • 104 Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005; 20 (04) 1090-1099
    CrossrefPubMedGoogle Scholar
  • 105 Wilkens J, Male V, Ghazal P. , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. J Immunol 2013; 191 (05) 2226-2235
    CrossrefPubMedGoogle Scholar
  • 106 Morikawa A, Ohara N, Xu Q. , et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod 2008; 23 (04) 944-951
    CrossrefPubMedGoogle Scholar
  • 107 Ohara N, Morikawa A, Chen W. , et al. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 2007; 14 (8, Suppl): 20-27
    PubMedGoogle Scholar
  • 108 Sasaki H, Ohara N, Xu Q. , et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2007; 92 (02) 616-623
    CrossrefPubMedGoogle Scholar
  • 109 Courtoy GE, Donnez J, Marbaix E, Dolmans MM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril 2015; 104 (02) 426-34.e1
    CrossrefPubMedGoogle Scholar
  • 110 Wilkens J, Chwalisz K, Han C. , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008; 93 (12) 4664-4671
    CrossrefPubMedGoogle Scholar
  • 111 Donnez J, Vázquez F, Tomaszewski J. , et al; PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101 (06) 1565-73.e1 , 18
    CrossrefPubMedGoogle Scholar
  • 112 Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005; 12 (03) 227-233
    CrossrefPubMedGoogle Scholar
  • 113 Mutter GL, Bergeron C, Deligdisch L. , et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21 (05) 591-598
    CrossrefPubMedGoogle Scholar
  • 114 Fuhrmann U, Hess-Stumpp H, Cleve A. , et al. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem 2000; 43 (26) 5010-5016
    CrossrefPubMedGoogle Scholar
  • 115 Heikinheimo O, Vani S, Carpén O. , et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod 2007; 22 (09) 2515-2522
    CrossrefPubMedGoogle Scholar
  • 116 Dinh A, Sriprasert I, Williams AR, Archer DF. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. Contraception 2015; 91 (05) 360-367
    CrossrefPubMedGoogle Scholar
  • 117 Hodgen GD, van Uem JF, Chillik CF. , et al. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod 1994; 9 (Suppl. 01) 77-81
    PubMedGoogle Scholar
  • 118 Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000; 65 (10-11): 741-751
    CrossrefPubMedGoogle Scholar
  • 119 Kettel LM, Murphy AA, Morales AJ, Rivier J, Vale W, Yen SS. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 1993; 60 (04) 642-646
    CrossrefPubMedGoogle Scholar
  • 120 Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76 (02) 513-517
    PubMedGoogle Scholar
  • 121 Murji A, Whitaker L, Chow TL, Sobel ML. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev 2017; 4: CD010770
    PubMedGoogle Scholar
  • 122 Donnez J, Donnez O, Matule D. , et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016; 105 (01) 165-173.e4
    CrossrefPubMedGoogle Scholar
  • 123 Schütt B, Kaiser A, Schultze-Mosgau MH. , et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod 2016; 31 (08) 1703-1712
    CrossrefPubMedGoogle Scholar
  • 124 Seitz C, Bumbuliene Ž, Costa AR. , et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemp Clin Trials 2017; 55: 56-62
    CrossrefPubMedGoogle Scholar
  • 125 Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update 2016; 22 (06) 665-686
    CrossrefPubMedGoogle Scholar
  • 126 LIBERTY 1: A Phase 3 randomized, double-blind, placebo-controlled efficacy & safety study of relugolix co-administered with/without estradiol and norethindrone acetate in women with heavy menstrual bleeding associated with uterine fibroids. Available at: https://clinicaltrials.gov/ct2/show/NCT03049735?term=Relugolix&rank=8;%20https://clinicaltri als.gov/ct2/show/NCT03103087?term=Relugolix&rank=7 . Accessed June 13, 2017
    PubMedGoogle Scholar
  • 127 A Phase 3, multicentre, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Available at: https://clinicaltrials.gov/ct2/show/NCT03070899?term=OBE2109&rank=3;%20https://clinicaltri als.gov/ct2/show/NCT03070951?term=OBE2109&rank=2 . Accessed June 13, 2017
    PubMedGoogle Scholar
  • 128 Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab 2017; 102 (05) 1683-1691
    CrossrefPubMedGoogle Scholar
  • 129 Struthers RS, Nicholls AJ, Grundy J. , et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009; 94 (02) 545-551
    CrossrefPubMedGoogle Scholar
  • 130 Diamond MP, Carr B, Dmowski WP. , et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci 2014; 21 (03) 363-371
    CrossrefPubMedGoogle Scholar
  • 131 Carr B, Dmowski WP, O'Brien C. , et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci 2014; 21 (11) 1341-1351
    CrossrefPubMedGoogle Scholar
  • 132 Taylor HS, Giudice LC, Lessey BA. , et al. Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist. N Engl J Med 2017; 377 (01) 28-40
    CrossrefPubMedGoogle Scholar
  • 133 Archer DF, Stewart EA, Jain RI. , et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril 2017; 108 (01) 152-160.e4
    CrossrefPubMedGoogle Scholar
  • 134 Stewart E, Owens C, Duan WR, Gao J, Chwalisz K, Simon JA. Elagolix alone and with add-back decreases heavy menstrual bleeding in women with uterine fibroids. [21 H]. Obstet Gynecol 2017; 129: 87S
    PubMedGoogle Scholar
  • 135 Miwa K, Hitaka T, Imada T. , et al. Discovery of 1-4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 2011; 54 (14) 4998-5012
    CrossrefPubMedGoogle Scholar
  • 136 MacLean DB, Shi H, Faessel HM, Saad F. Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): Phase 1 study in healthy males. J Clin Endocrinol Metab 2015; 100 (12) 4579-4587
    CrossrefPubMedGoogle Scholar